AR098142A1 - GENETIC MARKERS THAT PREACH THE RESPONSE TO THE GLATIRAMER ACETATE - Google Patents
GENETIC MARKERS THAT PREACH THE RESPONSE TO THE GLATIRAMER ACETATEInfo
- Publication number
- AR098142A1 AR098142A1 ARP140103954A ARP140103954A AR098142A1 AR 098142 A1 AR098142 A1 AR 098142A1 AR P140103954 A ARP140103954 A AR P140103954A AR P140103954 A ARP140103954 A AR P140103954A AR 098142 A1 AR098142 A1 AR 098142A1
- Authority
- AR
- Argentina
- Prior art keywords
- glatiramer acetate
- location
- subject
- group
- alleles
- Prior art date
Links
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
La presente provee un método para el tratamiento de un sujeto humano afectado por esclerosis múltiple o de un ataque clínico único compatible con la esclerosis múltiple con una composición farmacéutica que comprende acetato de glatiramer y un vehiculo farmacéuticamente aceptable, que comprende los pasos de: (i) determinar un genotipo del sujeto en una ubicación correspondiente a la ubicación de uno o más polimorfismos de nucleótido simple (SNP) seleccionados del grupo formado por: Grupo 1, (ii) identificar al sujeto como un respondedor predicho al acetato de glatiramer si el genotipo del sujeto contiene uno o más alelos A en la ubicación de Grupo 2, uno o más alelos C en la ubicación de Grupo 3, uno o más alelos G en la ubicación de Grupo 4, o uno o más alelos T en la ubicación de kgp18432055, kgp279772, kgp3991733 o kgp7242489; y (iii) administrar la composición farmacéutica que comprende acetato de glatiramer y un vehículo farmacéuticamente aceptable al sujeto solamente si el sujeto está identificado como un respondedor predicho al acetato de glatiramer. Kit. Sonda. Acetato de glatiramer o composición farmacéutica.This provides a method for the treatment of a human subject affected by multiple sclerosis or a single clinical attack compatible with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable vehicle, comprising the steps of: (i ) determine a genotype of the subject at a location corresponding to the location of one or more single nucleotide polymorphisms (SNPs) selected from the group consisting of: Group 1, (ii) identify the subject as a respondent predicted to glatiramer acetate if the genotype of the subject contains one or more alleles A at the location of Group 2, one or more alleles C at the location of Group 3, one or more alleles G at the location of Group 4, or one or more alleles T at the location of kgp18432055 , kgp279772, kgp3991733 or kgp7242489; and (iii) administering the pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier to the subject only if the subject is identified as a respondent predicted to glatiramer acetate. Kit. Probe. Glatiramer acetate or pharmaceutical composition.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361893807P | 2013-10-21 | 2013-10-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR098142A1 true AR098142A1 (en) | 2016-05-04 |
Family
ID=57867937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140103954A AR098142A1 (en) | 2013-10-21 | 2014-10-21 | GENETIC MARKERS THAT PREACH THE RESPONSE TO THE GLATIRAMER ACETATE |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR098142A1 (en) |
-
2014
- 2014-10-21 AR ARP140103954A patent/AR098142A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY35790A (en) | GENETIC MARKERS THAT PREACH THE RESPONSE TO THE GLATIRAMER ACETATE | |
| AR088294A1 (en) | DETERMINATION OF A SIMPLE NUCLEOTIDE POLYMORPHYSMS USEFUL TO PREACH THE CLINICAL RESPONSE TO GLATIRAMERO ACETATE | |
| CL2017001769A1 (en) | Compounds derived from nucleosides, nucleotides and analogs thereof; pharmaceutical composition comprising them; useful in the treatment of hepatitis c (divisional of the application 1699-2015). | |
| AU2018260866A1 (en) | Selective reduction of allelic variants | |
| UY34701A (en) | SOLID FORMS OF A THIOPHOSPHORAMIDATE NUCLEOTIDE PROFIT | |
| BR112015001839A2 (en) | deuterated ibrutinib | |
| BR112012030711A2 (en) | purinone derivative | |
| CR9315A (en) | METHODS AND SYSTEMS FOR DIAGNOSIS, FORECAST AND SELECTION OF THE TREATMENT OF LEUKEMIA | |
| SG10201804835VA (en) | Substituted nucleosides, nucleotides and analogs thereof | |
| MY165124A (en) | Semifluorinated alkane compositions | |
| UY35075A (en) | PREDICTIVE BIOMARKERS OF THE CLINICAL RESPONSE TO THE GLATIRÁMERO ACETATE | |
| CL2014000428A1 (en) | Method for the treatment of hepatitis c (hcv) comprising administering a compound of formula (i), (ii) or (iii) in combination with one or more therapeutic agents; pharmaceutical composition | |
| AR065984A1 (en) | SULFUR COMPOUNDS AS INHIBITORS OF THE SERINA PROTEASA NS3 OF THE HEPATITIS VIRUS C. PHARMACEUTICAL COMPOSITIONS. | |
| EP3498729A3 (en) | Therapeutic targets for alzheimer's disease | |
| MA40462A (en) | Method for the treatment of depression | |
| CO7131387A2 (en) | Compositions and methods of oligonucleotide chelate complex-polypeptides | |
| EP3626830A4 (en) | Apoe promoter single nucleotide polymorphism associated with alzheimer's disease risk and use thereof | |
| BR112013024880A2 (en) | hcv treatment selection | |
| AR104348A1 (en) | POLYMORPHISMS OF A SELECTED NUCLEOTIDE ONLY THAT ARE PREDICTIVE OF ANSWERS TO GLATIRAMBER ACETATE | |
| NZ621356A (en) | Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence | |
| AR098142A1 (en) | GENETIC MARKERS THAT PREACH THE RESPONSE TO THE GLATIRAMER ACETATE | |
| WO2012061808A3 (en) | Neuropsychiatric test reports | |
| MX2016012718A (en) | Determination of single nucleotide polymorphisms useful to predict response for rasagiline. | |
| MX2021008091A (en) | Composition comprising arthropods and astigmatid mite eggs. | |
| CO7160011A2 (en) | Azetidine and piperidine compounds useful as pde10 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |